101
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Familial aggregation of myasthenia gravis in affected families: a population-based study

, , , &
Pages 527-535 | Published online: 02 Nov 2017

Abstract

Introduction

Myasthenia gravis (MG) is clinically heterogeneous and can be life-threatening if bulbar or respiratory muscles are involved. However, relative contributions of genetic, shared, and nonshared environmental factors to MG susceptibility remain unclear. The aim of this study was to examine the familial aggregation and heritability of MG and the relative risks (RRs) of other autoimmune diseases in the relatives of patients with MG.

Methods

A population-based family study using the Taiwan National Health Insurance (NHI) Database was conducted. Participants included all individuals (N=23,422,955) who were actively registered in the NHI Database in 2013, 15,066 of whom had at least one first-degree relative with MG. We identified 8,638 parent–child relationships, 3,279 with an affected offspring, 3,134 with affected siblings, and 26 with affected twins. Prevalence and RRs of MG and other autoimmune diseases in the relatives of patients as well as the relative contributions of heritability, shared, and nonshared environmental factors to MG susceptibility were measured.

Results

RRs (95% confidence intervals [CIs]) for MG were 17.85 (8.71–36.56) for patients’ siblings, 5.33 (2.79–10.18) for parents, 5.82 (3.03–11.16) for offspring, and 1.42 (0.20–10.10) for spouses without genetic similarities. RRs (95% CIs) in individuals with a first-degree relative with MG were 2.18 (1.53–3.12) for systemic lupus erythematosus, 1.73 (1.09–2.74) for primary Sjögren’s syndrome, 1.90 (1.66–2.18) for autoimmune thyroid disease, and 1.68 (1.22–2.30) for rheumatoid arthritis. Accountability for the phenotypic variance of MG was 82.1% for familial transmission and 17.9% for nonshared environmental factors.

Conclusion

Individual risks of MG and other autoimmune diseases are increased in the relatives of patients with MG. Familial transmission of MG was estimated to be 82.1%.

Introduction

Myasthenia gravis (MG) is a heterogeneous neuromuscular autoimmune disease, occurring in different ethnic groups and both sexes. Clinical features of MG are diverse with mild ocular symptoms to severe generalized muscle weakness and disability. Prevalence and incidence of MG vary considerably. Incidence of MG ranges between 1.7 and 30 cases per million and its prevalence between 15 and 320 cases per million, depending on ethnicity and location.Citation1Citation3 The most recent estimate of MG prevalence in Taiwan was 140 cases per million population.Citation4

The etiology of MG is generally thought to involve a combination of genetic and environmental factors.Citation5 The magnitude of its genetic contribution is uncertain. However, a review of several familial cases of MGCitation6 suggests that familial factors play an important role in the pathogenesis of MG. Prior studies have shown that 1–7.1% of individuals with MG have a positive familial history for the disease.Citation7 The twin model has been used to estimate the contribution of genetic factors to disease risk and compare disease concordance between monozygotic and dizygotic twins. Ramanujam et alCitation8 showed that MG concordance was 35.5% in monozygotic twins compared to a dizygotic rate of 4–5%. Furthermore, MG has been reported to coaggregate with other autoimmune diseasesCitation9 and ~13% of MG patients reported other coexisting autoimmune diseases.Citation10 Moreover, genome-wide association studies (GWAS) have successfully identified at least 12 susceptible loci and numerous single-nucleotide polymorphisms to estimate the heritability associated with MG.Citation11

Few population-based studies have measured the contribution of genetic and environmental factors to MG susceptibility. Furthermore, estimates of the risk of MG and other autoimmune diseases have been associated with an MG family history and provide valuable information for genetic counseling in respect of affected families. In this study, we reconstructed a nationwide genealogy and linked the pedigrees to the health information from the National Health Insurance (NHI) Research Database, which covers the entire Taiwanese population. MG familial clustering was determined through estimating the risks of MG according to specific affected kinship links, and relative contributions of genetic, shared, and nonshared environmental factors to MG susceptibility were assessed. In addition, we further estimated the RRs of other autoimmune diseases in individuals with a positive MG family history.

Methods

Study population

This study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital, Taiwan (IRB 201600658B0), with an exemption from obtaining informed consent as all data involved were totally anonymized. We identified all NHI 2013 beneficiaries as our source population. Individuals without a valid insurance status were excluded from this analysis. The NHI coverage rate was over 99.5% in 2013.Citation12 The unique personal identification number assigned to each resident in Taiwan was used to permit valid internal linkages within the database. NHI database contained registration information and original claims data of all NHI beneficiaries, including birth date, sex, family relationships, vital statistics, place of residence, enrollment, employment categories, discharge dates, insurance fees, medical diagnoses, medical expenditures, operations, procedures, and dates of inpatient and outpatient visits.

Identification of first-degree relatives of MG patients

Methods to identify NHI Research Database first-degree relatives and familial associations have been reported previously.Citation13 In general, parent–offspring or spouse relationships can be directly identified, while full siblings can be identified through their parents. Twins were defined as full siblings with the same date of birth (±1 day), but twin zygosity could not be identified in the database. Individuals were grouped into families according to the relationship and correlation among individuals from the same family.Citation13 Among the 29,505,197 NHI beneficiaries (both alive and dead between March 1, 1995 and December 31, 2013), 7,856,663 individuals were registered as single, without any identifiable relative. The remaining 21,648,534 individuals were classified into 4,042,209 families. Overall, 22,689,489 parent–child relationships, 18,347,866 full sibling pairs, and 381,082 twin pairs were identified. Each individual may appear multiple times in different categories of family relationships depending on their family structure. Data analysis was conducted between January 1 and May 31, 2016.

Ascertainment of MG and other autoimmune diseases

Individuals suspected of having autoimmune diseases are usually referred to specialists for further diagnosis in Taiwan. A waiver, known as a catastrophic certificate, is given when the National Insurance Administration confirms the MG diagnosis, following a review and verification process undertaken by a commissioned expert panel. International classification of disease (ICD) 9 codes (358.00 and 358.01) for MG were included. ICD9 code 358.1 (myasthenic syndromes) was not included. In this study, patients diagnosed with MG or other autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome, and autoimmune thyroid disease, were identified as catastrophic illness patients and entitled to waive medical copayments. Information on the Registry for Catastrophic Illness Patients contains diagnosis, demographics, application date, the diagnosing physician, unique personal identification codes, and other administration data of beneficiaries with the certificate.

Covariates

Sex, age, occupation categories, income level quintiles, residential level of urbanization, and family size were considered as confounding factors that could modify the familial associations of MG.Citation14

Statistical analysis

MG prevalence was calculated for the general population and individuals with affected first-degree relatives. Those who were diagnosed as having MG, per MG definition, between January 1, 1996 and December 31, 2013, and had valid insurance registrations in 2013 were indicated as prevalent cases.

Relative risks (RRs) estimated in this study are essentially the relative recurrence risks according to the original Risch definition;Citation15 there are prevalence ratios between individuals with a specific type of affected relative and the general population. We used the Breslow-Cox proportional hazards model, which estimated the prevalence rate ratios in a cross-sectional study through applying a same follow-up time for all individuals. This method has been used to make consistent estimates for prevalence ratios close to true limits.Citation16 In addition, this model assumes independence among the participants. We used the marginal model to address potential bias because of within-family clustering.Citation17 The RR was adjusted for age, sex, socioeconomic factors, and family size. We calculated RRs for individuals with affected first-degree relatives of any kinship and for individual kinships (parent, offspring, sibling, and twin). We excluded twins from the sibling analyses. In addition to first-degree relatives, we estimated RRs for spouses. We excluded all half-sibling from analysis.

Heritability was defined as the phenotypic variance proportion that is attributable to genetic factors; familial transmission involved the sum of heritability and shared environmental contributions. Both familial transmission and heritability can be calculated with the polygenic liability model.Citation18 In this study, we used the threshold liability model to estimate these variables.Citation19 The original model assumes no effect on common environmental variance; thus, familial transmission equals heritability. We also restricted the family history to first-degree relatives and assumed a mean of two siblings in a family. MG-associated thymoma was also analyzed. We further estimated the familial co-aggregation extent of other autoimmune diseases in affected families using the marginal Cox proportional hazards model, with a same follow-up time for all participants adjusting for age, sex, place of residence, income levels, occupation, and family size. RRs of RA, SLE, primary Sjögren’s syndrome, and autoimmune thyroid disease were estimated as the adjusted prevalence ratios of specified autoimmune diseases between individuals with affected first-degree relatives and those without an MG family history. All analyses were performed using the SAS, Version 9.3 (SAS Institute Inc., Cary, NC, USA), and two-sided P-values £0.05 were considered statistically significant.

Results

MG prevalence in individuals with affected first-degree relatives versus the general population

The study population comprised 23,422,955 individuals enrolled in the NHI Research Database in Taiwan in 2013. Among them, the proportions of individuals with a known parent, child, sibling, or twin were 47.45, 57.45, 47.29, and 1.51%, respectively. We identified 6,638 patients diagnosed with MG, giving a crude prevalence of 0.028%. In the general population of Taiwan in 2013, 15,066 (0.064%) individuals had at least one first-degree relative with MG: 8,638 with affected parents, 3,279 with an affected offspring, 3,134 with affected siblings, and 26 with affected twins. The mean ± SD age of the MG patients was lower in those with a family history of MG (36.3±18.3 years) than in those without a family history (39.0±20.9 years; P<0.001 using the Student’s t-test). MG prevalence in the first-degree relatives with a family history was higher (0.205%) than in those without a family history (0.028%). Age-specific MG prevalence was higher in individuals with affected first-degree relatives with MG than in the general population (). Furthermore, onset age-specific MG prevalence was markedly higher in individuals with affected first-degree relatives than in the general population in two age onset group fields (0–9 and 30–39) (). Other characteristics of the study population are shown in . In addition, there were 8.21% of MG patients who had thymoma compared to 0.01% in the general population.

Figure 1 Age-specific prevalence of myasthenia gravis in individuals with a first-degree (circle) relative affected with MG and in the general population (hollow circle) in Taiwan in 2013.

Note: This figure demonstrates a significantly higher prevalence of MG in most age bands among those with a family history than the general population.
Abbreviation: MG, myasthenia gravis.
Figure 1 Age-specific prevalence of myasthenia gravis in individuals with a first-degree (circle) relative affected with MG and in the general population (hollow circle) in Taiwan in 2013.

Figure 2 Comparison of the onset age of MG in affected patients with (circle) and without (hollow circle) a family history in 2013.

Abbreviation: MG, myasthenia gravis.
Figure 2 Comparison of the onset age of MG in affected patients with (circle) and without (hollow circle) a family history in 2013.

Table 1 Baseline characteristics of individuals with affected first-degree relatives with myasthenia gravis and the general population

RRs for MG in individuals with affected first-degree relatives

shows the prevalence (RR) of MG in individuals with affected first-degree relatives, according to different relationships and sexes of the affected individuals and their families. Overall, having affected first-degree relatives with MG was associated with an adjusted RR of 7.78 (95% confidence interval [CI] 4.80–12.60) for the disease. Individuals with male- and female-affected relatives had respective MG RRs of 7.50 (95% CI 3.93.15–14.33) and 8.01 (95% CI 4.46–14.41), suggesting that the sex of the affected relative did not influence the RR. In MG, the genetic distance degree among family relatives is associated with RRs. RRs of MG were 17.85 (95% CI 8.71–36.56) in siblings, 5.82 (95% CI 3.03–11.16) in offspring, and 5.33 (95% CI 2.79–10.18) in parents.

Table 2 Relative risks for myasthenia gravis in first-degree relatives

Coaggregation of other autoimmune diseases

shows the adjusted RRs (95% CIs) for other autoimmune diseases in individuals with affected first-degree relatives than in the general population. RR in individuals with first-degree relatives affected with MG was 2.18 (1.53–3.12) for SLE, 1.73 (1.09–2.74) for primary Sjögren’s syndrome, 1.68 (1.22–2.30) for RA, and 1.90 (1.66–2.18) for autoimmune thyroid disease.

Table 3 Relative risks of other autoimmune diseases in individuals with affected first-degree relatives affected with myasthenia gravis

Familial resemblance and heritability of MG

Using the threshold liability model, we estimated that the accountability for the phenotypic variance of MG was 82.1% for familial transmission and 17.9% for nonshared environmental factors. Given the parameters estimated previously, the probability of the case of an MG patient to be sporadic was 83.5%.

Discussion

This population-based study investigated the risk of MG in individuals with affected first-degree relatives and estimated the heritability and familial transmission of the disease in the general population. Prevalence of MG in the relatives of patients is 7.78-fold higher than in the general population. We observed that genetic distance is associated with the amplitude of risk, and heritability was estimated to be 75.8%. Most MG cases are expected to be sporadic. Furthermore, a higher prevalence of other autoimmune diseases is noted in individuals with affected first-degree relatives than in the general population. Our results indicate several implications. First, the study provides objective quantitative data to evaluate the RRs, familial transmission, and sporadic proportion of MG patients, which are valuable in clinical estimation. Second, information from large populations may help future genetic studies to estimate candidate genes. Third, coaggregation and overlapping pathogenesis of MG with other autoimmune diseases need further elucidations.

Several studies on families with MG patients have been reported.Citation7 However, investigation of familial aggregation and evidence for familial or genetic contributions are rare. This study provides evidence to support the importance of familial effects in MG susceptibility. Familial occurrence of MG is estimated at ~1–7.3%.Citation20 Familial MG tends to occur at a younger age, but some also develop late-onset MG cases (with an onset age of ≥65 years).Citation21 In general, the incidence of younger-onset MG is higher than elderly onset MG.Citation20 However, its incidence has shifted to an advanced age group due to some environmental factors.Citation22 In our study, age-specific MG prevalence was generally higher in the first-degree relatives of MG patients than in the general population. Onset age-specific MG prevalence was particularly higher in the younger-aged individuals than in the general population. Sex is an important confounding factor in several autoimmune diseases.Citation23 Most early-onset MG patients comprise a greater number of women.Citation24 A recent study suggested that women are more predisposed to MG than men because of some risk alleles.Citation5 However, sex differences in MG were not found in the present study. According to the genetic distance analysis, sibling RRs were higher than parental or offspring RRs under the same genetic distance, suggesting that shared environmental factors also contribute to MG susceptibility. Using the polygenic liability model, we estimated that 75.8% of the phenotypic variance can be explained due to familial factors and most MG cases appeared to be sporadic rather than familial.

MG has been studied for >30 years, and genetic factors were thought to contribute to its development. Previous reports showed that the human leukocyte antigen (HLA) locus remains the main genetic risk factor for MG.Citation25 GWAS cases from European and American populations provide an evidence that major histocompatibility complex class II locus, TNIP1, and PTPN22 have been suggested as susceptibility factors for autoimmune MG.Citation26 In addition, the CTLA4 gene has been found to be involved in MG.Citation5,Citation27 HLA-B*08, PTPN22, and TNIP1 were also associated with an early-onset MG.Citation26

Aside from genetic factors contributing to MG, shared environmental factors also play a key role in familial clustering of MG. Previous reports have shown that lower socioeconomic status,Citation28 start of smoking at an early age,Citation28 hepatitis virus (B or C) infection,Citation29 and the postpartum periodCitation30 are important environmental MG risk factors, which are dependent on geographical variations.Citation31 We modified the work of Lai and TsengCitation4 and reviewed previous epidemiological studies of MG ().Citation31Citation40 In Northern Europe, the prevalence of MG subgroups is lower in Norway than in the Netherlands, and differences in geographical north–south gradients have also been found between these populations.Citation31 Genetic and environmental factors are likely to be associated with MG in different areas and reflect gene–environmental interactions.Citation40 The etiology of MG is possibly affected depending on geographical variations. Studies have reported that hepatitis infected patients are potentially at a higher risk of MG.Citation29 In addition, socioeconomic status and smoking habits may also affect MG development.Citation28 Therefore, this implies that both genetic and shared environmental factors may influence the phenotypic variance in MG. This study uses the threshold liability model to separate shared and nonshared environmental factors. We compared the liability scale between siblings and spouses in a population setting, which assumes that spouses share environmental factors and siblings share both genes and family environment. Therefore, a further comparison with liability of the general population could partition the phenotypic variance into shared, nonshared, and genetic contributions. We considered age, sex, and socioeconomic factors in the regression model to estimate familial RR, but the model ensures that the overall variations contributed by all the factors are used.

Table 4 Epidemiological studies of MG in different countries

Familial risk and coaggregation of autoimmune diseases with MG have not been studied well. A previous systematic review analyzed English language studies on MG subtypes from 1960 to 2010, and the pooled estimate was 13% (95% CI 12–14%) for MG with coexisting autoimmune diseases.Citation10 Recent reports have shown that autoimmune thyroid diseases share a lot of these factors with RA and SLE, which is expected as RA and SLE often coexist with MG.Citation41 Our results suggest that some autoimmune diseases contribute to MG pathogenesis, but the magnitude of overlapping factors contributing to the disease manifestation is different. The national population data of familial autoimmune disease co-aggregation provide useful information for counseling families of patients with MG.

There are some limitations in this study. First, the NHI Research Database is primarily a health insurance database, which lacks complete information on laboratory data, physical examinations, and clinical findings. Classification of MG cases was through the patients’ diagnoses recorded in the registry with catastrophic illnesses or classification depended on primary care records. However, all MG diagnoses require strong medical evidence to issue catastrophic illness certificates. Therefore, misclassification is considered rare and is unlikely to affect our conclusion. Patients with less severe diseases may not have received a certificate; therefore, they were not identified as cases. Furthermore, the number of these cases is thought to be small. Patients with MG stratified by antibody status were mainly classified into acetylcholine receptor, muscle-specific kinase, lipoprotein related protein 4, and agrin subsets.Citation42 As cause and classification of MG subgroup by antibody status could not be analyzed with the health insurance secondary database, this remains a limitation of this study. Second, some first-degree relative MG sporadic cases may have been lost. Third, our results are limited to the population of Taiwan. Further studies outside of Taiwan are needed. We considered that there was little chance for misclassification. However, it is likely that the total number of MG cases is an underestimation as milder forms of the disease may not have qualified for a catastrophic certificate.

Conclusion

This nationwide family study confirms that an MG family history is associated with a high risk for the disease. Differential risk associated with different kinships suggests a strong genetic component in MG susceptibility. An MG family history also confers an elevated risk of other autoimmune diseases. Our findings may help improve the design of future familial and genetic MG risk studies and may also be useful in counseling families of patients with MG.

Acknowledgments

This study was based in part on data from the NHIRD provided by the Bureau of National Health Insurance, Department of Health, and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent the views of the Bureau of National Health Insurance, Department of Health, or of the National Health Research Institutes. This work was funded by the National Science Council of Taiwan (project nos 103-2314-B-182A-070-MY2 and 103-2314-B-182-043-MY2) and Chang Gung Memorial Hospital (project nos CMRPG3F1011, CMRPG3D1671, and CORPG3E0131).

Disclosure

The authors report no conflicts of interest in this work.

References

  • CarrASCardwellCRMcCarronPOMcConvilleJA systematic review of population based epidemiological studies in myasthenia gravisBMC Neurol2010104620565885
  • McGroganASneddonSde VriesCSThe incidence of myasthenia gravis: a systematic literature reviewNeuroepidemiology201034317118320130418
  • BreinerAWiddifieldJKatzbergHDBarnettCBrilVTuKEpidemiology of myasthenia gravis in Ontario, CanadaNeuromuscul Disord2016261414626573434
  • LaiCHTsengHFNationwide population-based epidemiological study of myasthenia gravis in TaiwanNeuroepidemiology2010351667120523074
  • SunLMengYXieYCTLA4 variants and haplotype contribute genetic susceptibility to myasthenia gravis in northern Chinese populationPLoS One201497e10198625003519
  • FengHYLiuWBLuoCMA retrospective review of 15 patients with familial myasthenia gravis over a period of 25 yearsNeurol Sci201233477177722057263
  • SalvadoMCanelaMPonsetiJMStudy of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohortJ Neurol Sci201636011011426723985
  • RamanujamRPirskanenRRamanujamSHammarstromLUtilizing twins concordance rates to infer the predisposition to myasthenia gravisTwin Res Hum Genet201114212913621425894
  • Bello-SaniFAnumahFEBakariAGMyasthenia gravis associated with autoimmune thyroid disease: a report of two patientsAnn Afr Med200872889019143167
  • MaoZFYangLXMoXAFrequency of autoimmune diseases in myasthenia gravis: a systematic reviewInt J Neurosci2011121312112921142828
  • GiraudMVandiedonckCGarchonHJGenetic factors in autoimmune myasthenia gravisAnn N Y Acad Sci2008113218019218567868
  • Bureau of National Health Insurance, Department of Health, Executive Yuan [webpage on the Internet]The National Health Insurance Statistics2013 Available from: http://www.nhi.gov.tw/English/webdata/web-data.aspx?menu=11&menu_id=296&WD_ID=296&webdata_id=4645Accessed September 14, 2014
  • KuoCFGraingeMJValdesAMFamilial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected familiesJAMA Intern Med20151751518152626193127
  • LiuCYHungYTChuangYLChenYJWengWSLiuJSIncorporating development stratification of Taiwan townships into sampling design of large scale health interview surveyJ Health Manag200614122
  • RischNLinkage strategies for genetically complex traits. I. Multilocus modelsAm J Hum Genet19904622222282301392
  • BarrosAJHirakataVNAlternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratioBMC Med Res Methodol200332114567763
  • LinDYCox regression analysis of multivariate failure time data: the marginal approachStat Med19941321223322477846422
  • ReichTRiceJCloningerCRWetteRJamesJThe use of multiple thresholds and segregation analysis in analyzing the phenotypic heterogeneity of multifactorial traitsAnn Hum Genet1979423371390434779
  • KuoCFGraingeMJSeeLCFamilial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in TaiwanAnn Rheum Dis201574236937424265412
  • MuraiHYamashitaNWatanabeMCharacteristics of myasthenia gravis according to onset-age: Japanese nationwide surveyJ Neurol Sci20113051–29710221440910
  • HirunagiTTsujikawaKHasegawaYManoKKatsunoMElderly-onset familial myasthenia gravis in two siblingsNeuromuscul Disord201626634734927132121
  • CasettaIGroppoEDe GennaroRMyasthenia gravis: a changing pattern of incidenceJ Neurol2010257122015201920623298
  • NgoSTSteynFJMcCombePAGender differences in autoimmune diseaseFront Neuroendocrinol201435334736924793874
  • MeriggioliMNSandersDBAutoimmune myasthenia gravis: emerging clinical and biological heterogeneityLancet Neurol20098547549019375665
  • VincentAPalaceJHilton-JonesDMyasthenia gravisLancet200135792742122212811445126
  • GregersenPKKosoyRLeeATRisk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08Ann Neurol201272692793523055271
  • WangXBPirskanenRGiscombeRLefvertAKTwo SNPs in the promoter region of the CTLA-4 gene affect binding of transcription factors and are associated with human myasthenia gravisJ Intern Med20082631616918088253
  • ManiaolAHBoldinghMBrunborgCHarboHFTallaksenCMSmoking and socio-economic status may affect myasthenia gravisEur J Neurol201320345346022934661
  • HalfonPLevyMSan MarcoMMyasthenia gravis and hepatitis C virus infectionJ Viral Hepat1996363293328947885
  • BoldinghMIManiaolAHBrunborgCWeedon-FekjaerHVerschuurenJJTallaksenCMIncreased risk for clinical onset of myasthenia gravis during the postpartum periodNeurology201687202139214527770065
  • BoldinghMIManiaolAHBrunborgCGeographical distribution of myasthenia gravis in northern Europe – results from a population-based study from two countriesNeuroepidemiology201544422123126068011
  • ChristensenPBJensenTSTsiropoulosIIncidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989Neurology1993439177917838414031
  • TolaMRCaniattiLMCasettaIImmunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern ItalyActa Neurol Scand19949053183237887131
  • RobertsonNPDeansJCompstonDAMyasthenia gravis: a population based epidemiological study in Cambridgeshire, EnglandJ Neurol Neurosurg Psychiatry19986544924969771771
  • PoulasKTsibriEKoklaAEpidemiology of seropositive myasthenia gravis in GreeceJ Neurol Neurosurg Psychiatry200171335235611511710
  • FangFSveinssonOThormarGThe autoimmune spectrum of myasthenia gravis: a Swedish population-based studyJ Intern Med2015277559460425251578
  • YuYLHawkinsBRIpMSWongVWooEMyasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult diseaseActa Neurol Scand19928621131191414218
  • PedersenEGHallasJHansenKJensenPEGaistDLate-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996–2009Eur J Neurol201320230931422882327
  • LeeHSLeeHSShinHYChoiYCKimSMThe epidemiology of myasthenia gravis in KoreaYonsei Med J201657241942526847295
  • MontomoliCCitterioAPiccoloGEpidemiology and geographical variation of myasthenia gravis in the province of Pavia, ItalyNeuroepidemiology201238210010522377708
  • TamerSGokce GunesHNGokcalEYoldasTKCoexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravisNeurol India2016641454926754991
  • GilhusNEVerschuurenJJMyasthenia gravis: subgroup classification and therapeutic strategiesLancet Neurol201514101023103626376969